Elisa Ebrille1, Tomas Konecny2, Dana Konecny2, Radim Spacek3, Paul Jones4, Pavel Ambroz5, Christopher V DeSimone6, Brian D Powell7, David L Hayes6, Paul A Friedman6, Samuel J Asirvatham8. 1. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN; Department of Medical Sciences, Division of Cardiology, Città della Salute e della Scienza, University of Turin, Turin, Italy. 2. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN; International Clinical Research Center, St Anne's University Hospital, Brno, Czech Republic. 3. Department of Internal Medicine, Hospital Frýdek-Místek, Frýdek-Místek, Czech Republic. 4. Boston Scientific, St Paul, MN. 5. Astronomical Institute of the Academy of Sciences of the Czech Republic, Ondrejov. 6. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN. 7. Division of Cardiovascular Diseases, Sanger Heart & Vascular Institute, Charlotte, NC. 8. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN; Department of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, MN. Electronic address: asirvatham.samuel@mayo.edu.
Abstract
OBJECTIVE: To investigate a potential relationship between implantable cardioverter defibrillator (ICD) therapies and daily geomagnetic activity (GMA) recorded in a large database. PATIENTS AND METHODS: The ALTITUDE database, derived from the Boston Scientific LATITUDE remote monitoring system, was retrospectively analyzed for the frequency of ICD therapies. Daily GMA was expressed as the planetary K-index and the integrated A-index and was graded as levels I (quiet), II (unsettled), III (active), and IV (storm). RESULTS: A daily mean ± SD of 59,468±11,397 patients were monitored between January 1, 2009, and May 15, 2012. The distribution of days according to GMA was as follows: level I, 924/1231 (75%); level II, 226/1231 (18%); level III, 60/1231 (5%); and level IV, 21/1231 (2%). The daily mean ± SD numbers of ICD shocks received per 1000 active patients in the database were 1.29±0.47, 1.17±0.46, 1.03±0.37, and 0.94±0.29 on level I, II, III, and IV days, respectively; the daily mean ± SD sums of shocks and antitachycardia pacing therapies were 9.29±2.86, 8.46±2.45, 7.92±1.80, and 7.83±2.28 on quiet, unsettled, active, and storm days, respectively. A significant inverse relationship between GMA and frequency of ICD therapies was identified, with the most pronounced difference between level I and level IV days (P<.001 for shocks; P=.008 for shocks + antitachycardia pacing). CONCLUSION: In a large-scale cohort analysis, ICD therapies were delivered less frequently on days of higher GMA, confirming the previous pilot data and suggesting that higher GMA does not pose an increased risk of arrhythmias using ICD therapies as a surrogate marker. Further studies are needed to gain an in-depth understanding of the underlying mechanisms.
OBJECTIVE: To investigate a potential relationship between implantable cardioverter defibrillator (ICD) therapies and daily geomagnetic activity (GMA) recorded in a large database. PATIENTS AND METHODS: The ALTITUDE database, derived from the Boston Scientific LATITUDE remote monitoring system, was retrospectively analyzed for the frequency of ICD therapies. Daily GMA was expressed as the planetary K-index and the integrated A-index and was graded as levels I (quiet), II (unsettled), III (active), and IV (storm). RESULTS: A daily mean ± SD of 59,468±11,397 patients were monitored between January 1, 2009, and May 15, 2012. The distribution of days according to GMA was as follows: level I, 924/1231 (75%); level II, 226/1231 (18%); level III, 60/1231 (5%); and level IV, 21/1231 (2%). The daily mean ± SD numbers of ICD shocks received per 1000 active patients in the database were 1.29±0.47, 1.17±0.46, 1.03±0.37, and 0.94±0.29 on level I, II, III, and IV days, respectively; the daily mean ± SD sums of shocks and antitachycardia pacing therapies were 9.29±2.86, 8.46±2.45, 7.92±1.80, and 7.83±2.28 on quiet, unsettled, active, and storm days, respectively. A significant inverse relationship between GMA and frequency of ICD therapies was identified, with the most pronounced difference between level I and level IV days (P<.001 for shocks; P=.008 for shocks + antitachycardia pacing). CONCLUSION: In a large-scale cohort analysis, ICD therapies were delivered less frequently on days of higher GMA, confirming the previous pilot data and suggesting that higher GMA does not pose an increased risk of arrhythmias using ICD therapies as a surrogate marker. Further studies are needed to gain an in-depth understanding of the underlying mechanisms.
Authors: Sony Jacob; Sidakpal S Panaich; Rahul Maheshwari; John W Haddad; Benzy J Padanilam; Sinoj K John Journal: Europace Date: 2011-05-26 Impact factor: 5.214
Authors: Carolina L Zilli Vieira; Mark S Link; Eric Garshick; Adjani A Peralta; Heike Luttmann-Gibson; Francine Laden; Man Liu; Diane R Gold; Petros Koutrakis Journal: Europace Date: 2022-05-03 Impact factor: 5.486
Authors: Lucas Marzec; Sridharan Raghavan; Farnoush Banaei-Kashani; Seth Creasy; Edward L Melanson; Leslie Lange; Debashis Ghosh; Michael A Rosenberg Journal: PLoS One Date: 2018-10-29 Impact factor: 3.240